Edwards Lifesciences CFO Scott Ullem to step down by mid-2026

Reuters

Oct 31

Oct 30 (Reuters) - Edwards Lifesciences EW.N said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.

Ullem, who joined the company in 2014, helped guide its expansion in structural heart therapies and shift toward underserved markets. The company said the planned transition will ensure continuity.

The announcement came alongside the company's third-quarter results, which beat Wall Street estimates. Sales rose 14.7% to $1.55 billion, driven by strong demand across its transcatheter valve therapies, compared with estimates of $1.49 billion according to data compiled by LSEG.

Shares of the company were up about 3% in after-market trading.

The company also raised its full-year sales and profit forecasts.

(Reporting by Anshi Sancheti in Bengaluru; Editing by Alan Barona)

((Anshi.Sancheti@thomson.reuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2579852170"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579852170\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579852170?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 04:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579852170","market":"us","top_or_hot":-1,"title":"Edwards Lifesciences CFO Scott Ullem to step down by mid-2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Edwards Lifesciences CFO Scott Ullem to step down by mid-2026</title></head><body><p>\n<span>Oct 30 (Reuters)</span><span> - </span>Edwards Lifesciences <span>EW.N</span> said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.</p><p>Ullem, who joined the company in 2014, helped guide its expansion in structural heart therapies and shift toward underserved markets. The company said the planned transition will ensure continuity.</p><p>The announcement came alongside the company's third-quarter results, which beat Wall Street estimates. Sales rose 14.7% to $1.55 billion, driven by strong demand across its transcatheter valve therapies, compared with estimates of $1.49 billion according to data compiled by LSEG.</p><p>Shares of the company were up about 3% in after-market trading.</p><p>The company also <span>raised its full-year</span> sales and profit forecasts.</p><p> (Reporting by Anshi Sancheti in Bengaluru; Editing by Alan Barona)</p><p> ((Anshi.Sancheti@thomson.reuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edwards Lifesciences CFO Scott Ullem to step down by mid-2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdwards Lifesciences CFO Scott Ullem to step down by mid-2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-31 04:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Edwards Lifesciences CFO Scott Ullem to step down by mid-2026</title></head><body><p>\n<span>Oct 30 (Reuters)</span><span> - </span>Edwards Lifesciences <span>EW.N</span> said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.</p><p>Ullem, who joined the company in 2014, helped guide its expansion in structural heart therapies and shift toward underserved markets. The company said the planned transition will ensure continuity.</p><p>The announcement came alongside the company's third-quarter results, which beat Wall Street estimates. Sales rose 14.7% to $1.55 billion, driven by strong demand across its transcatheter valve therapies, compared with estimates of $1.49 billion according to data compiled by LSEG.</p><p>Shares of the company were up about 3% in after-market trading.</p><p>The company also <span>raised its full-year</span> sales and profit forecasts.</p><p> (Reporting by Anshi Sancheti in Bengaluru; Editing by Alan Barona)</p><p> ((Anshi.Sancheti@thomson.reuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BYQQ9H92.USD","symbol_name":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL6N3WB15M:1","article_id":"2579852170","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579852170","pubTimestamp":1761856602,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Edwards Lifesciences CFO Scott Ullem to step down by mid-2026 Oct 30 (Reuters) - Edwards Lifesciences EW.N said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remai","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","BK4082":"医疗保健设备","BK4588":"碎股","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4504":"桥水持仓","BK4567":"ESG概念","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","EW":"爱德华兹","BK4585":"ETF&股票定投概念"},"translate_title":"Edwards Lifesciences首席财务官Scott Ullem将于2026年中期辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":0.9},"content_text":"Edwards Lifesciences CFO Scott Ullem to step down by mid-2026\nOct 30 (Reuters) - Edwards Lifesciences EW.N said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.Ullem, who joined the company in 2014, helped guide its expansion in structural heart therapies and shift toward underserved markets. The company said the planned transition will ensure continuity.The announcement came alongside the company's third-quarter results, which beat Wall Street estimates. Sales rose 14.7% to $1.55 billion, driven by strong demand across its transcatheter valve therapies, compared with estimates of $1.49 billion according to data compiled by LSEG.Shares of the company were up about 3% in after-market trading.The company also raised its full-year sales and profit forecasts. (Reporting by Anshi Sancheti in Bengaluru; Editing by Alan Barona) ((Anshi.Sancheti@thomson.reuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}